glp 1 replenza Replenza™ GLP-1 Support Daily Replenisher Mixed Berry Powder, 6.8 oz Replenza debuts nutritional support system

Goldman Sachs forecasts that the global weight-loss drug market will reach USD 114 billion by 2030, an upward revision of 13% from last years estimate

Novo Nordisk is evaluating a long-acting semaglutide implant designed to keep GLP-1 patients on treatment for months at a time and food and drink manufacturers should be watching closely.

patients in pill form, expanding access to clinically proven weight-loss and cardiovascular risk-reduction therapy with broad affordability options.

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

New weight-loss pill may be more accessible than injections

If the discoveries that gave us Ozempic and Mounjaro find their way to the Nobel spotlight, who would win